Clearly, we can learn much about LRRK2 activation by looking at close homologs that have been studied for a longer time, and hopefully this will facilitate the discovery of new therapeutic strategies for attacking LRRK2 as a driver of PD. The gene discussed is LRRK2; the disease is Parkinson disease.